Valeant wants Allergan shareholders to see growth at Bausch & Lomb

Valeant ($VRX), which is trying to overcome resistance from the management of Allergan ($AGN) for its $53 billion buyout offer, has filed a new presentation with the SEC in preparation for an investor meeting. Refuting Allergan's contention that its growth has been mostly tied to its nonstop M&A action, Valeant says the data shows 12% organic growth at Bausch & Lomb since it bought it out last year and takes credit for 90% of that improvement. The announcement does not mention the thousands of employees who got the boot as a result of the merger. Release | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.